Status:
COMPLETED
A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-0...
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects of non childbearing potential.
- Body Mass Index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight \>50 kg
- Subjects with fasting TG level of \>=90 mg/dL and \<=500 mg/dL following an overnight fast
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT02208284
Start Date
August 1 2014
End Date
December 1 2014
Last Update
March 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Haven Clinical Research Unit
New Haven, Connecticut, United States, 06511